Background/Objectives: The Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma (HCC) was updated in 2022 to refine patient stratification, particularly in patients with intermediate-stage (BCLC B) HCC. Although transarterial chemoembolization (TACE) remains a key treatment for these patients, there is no prognostic model for survival outcomes based on the pretreatment factors of patients who meet the updated 2022 BCLC indications for TACE. The aim of this study was to develop a pretreatment risk model predicting overall survival (OS) in patients with intermediate-stage HCC and reclassified as candidates for TACE according to the updated 2022 BCLC criteria. Methods: This retrospective study included 658 HCC patients treated with first-line TACE according to the updated BCLC 2022 guidelines. Pretreatment factors such as the Child–Pugh score, tumor burden (up-to-11 criteria), bilobar tumor involvement, and serum alpha-fetoprotein (AFP) levels were analyzed. Cox proportional hazards models were used to identify significant predictors of OS, with these factors subsequently incorporated into a risk prediction model. Results: Significant predictors of OS included Child–Pugh score ≥ 7, bilobar tumor involvement, beyond up-to-11 criteria, and AFP ≥ 400 ng/mL. A risk model was developed using these factors, stratifying patients into low-, intermediate-, and high-risk groups. The median OS in the low-, intermediate-, and high-risk groups was 53, 35, and 21 months, respectively. Conclusions: The proposed pretreatment risk prediction model may be useful for predicting OS and guiding TACE candidacy in intermediate-stage HCC patients based on the updated 2022 BCLC guidelines.
Background/Objectives: Management of hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) varies between systemic immunotherapy and locoregional approaches. We compared atezolizumab plus bevacizumab (Atezo–Bev) with locoregional therapy in treatment-naïve patients. Methods: We conducted a retrospective cohort study of patients with image- or biopsy-proven HCC and MVI, Child–Pugh A/B, and ECOG 0–1 who received first-line Atezo–Bev or locoregional therapy (transarterial chemoembolization [TACE] with or without external-beam radiotherapy [RT]). Inverse probability of treatment weighting (IPTW) minimized baseline imbalances. Primary outcomes were overall survival (OS) and progression-free survival (PFS). Modified RECIST assessed radiologic response, and major adverse events were classified using Society of Interventional Radiology criteria. Results: We analyzed 475 patients (Atezo–Bev, n = 191; locoregional therapy, n = 284). Baseline characteristics were similar, and IPTW achieved covariate balance. Median OS was 9.3 months with Atezo–Bev and 10.8 months with locoregional therapy; after IPTW, OS remained comparable (hazard ratio [HR] 0.95; 95% CI 0.76–1.19; p = 0.635). Median PFS was 6.0 versus 4.1 months, favoring Atezo–Bev; this persisted after IPTW (HR 0.64; 95% CI 0.52–0.79; p < 0.001). Objective response rates were similar (45% vs. 48%; p = 0.49). Major adverse events occurred in 11% of patients in both groups. Subgroup analyses showed no OS differences and a consistent PFS advantage with Atezo–Bev. Conclusions: In HCC with MVI, first-line Atezo–Bev achieved longer PFS than locoregional therapy, with comparable OS and safety, supporting Atezo–Bev as a valid and effective first-line option for disease control while locoregional modalities remain relevant within multidisciplinary care.
Background/Objectives: To evaluate the technical feasibility, safety, and therapeutic outcomes of the transradial approach for drug-eluting bead transarterial chemoembo-lization (DEB-TACE) as a patient-centric alternative to the conventional transfemoral route. Methods: Between August 2018 and August 2022, patients with unresectable hepato-cellular carcinoma (HCC) eligible for DEB-TACE were prospectively enrolled in this study (ClinicalTrials.gov identifier: NCT07160374). To prevent radial artery spasm and occlusion, a standardized intra-arterial cocktail solution containing 3,000 IU of heparin, 200 μg of nitroglycerin, and 2.5 mg of verapamil was administered immediately after sheath insertion. The primary endpoint was technical success without crossover to the femoral approach. Secondary endpoints included safety profile, tumor response, and procedural parameters. Results: A total of 37 patients were enrolled. Technical success was achieved in 100% of patients using the transradial approach, with zero crossover to the transfemoral ap-proach. A single major adverse event (liver abscess) occurred (2.7%). Radial artery pa-tency was preserved in all patients. All patients achieved immediate post-procedural ambulation. The objective response rate was 73% at first follow-up visit (median, 35 days; range, 14–60 days). The mean fluoroscopy time was 24 ± 9 minutes, and the mean dose area product was 142 ± 182 Gy·cm². Conclusions: The transradial approach demonstrated high technical success and a fa-vorable safety profile for DEB-TACE without increasing radiation exposure. These findings suggest that this method represents a feasible and effective alternative to the conventional transfemoral route.